See the DrugPatentWatch profile for hadlima
The cost of Hadlima (adalimumab-aqvh) varies based on several factors, including insurance coverage, pharmacy, and dosage. As a biosimilar to Humira, its pricing is designed to be competitive.
What is Hadlima?
Hadlima is a biosimilar to adalimumab, a medication used to treat various inflammatory conditions. It is an injection that targets tumor necrosis factor-alpha (TNF-alpha), a substance in the body that causes inflammation. Hadlima is approved for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1].
How much does Hadlima cost?
Specific retail prices for Hadlima are not publicly disclosed as they can fluctuate. However, as a biosimilar, it is generally expected to be less expensive than its reference product, Humira. The actual out-of-pocket cost for a patient will depend on their insurance plan, including deductibles, copays, and coinsurance. Manufacturer coupons or patient assistance programs may also be available to help reduce costs for eligible individuals.
When did Hadlima become available?
Hadlima was approved by the U.S. Food and Drug Administration (FDA) in July 2019. Its launch was subsequently delayed due to patent litigation with AbbVie, the manufacturer of Humira. Hadlima became available in the U.S. in July 2023 [1].
How does Hadlima compare to Humira?
Hadlima is a biosimilar to Humira (adalimumab). Biosimilars are highly similar to their reference products and demonstrate no clinically meaningful differences in terms of safety, purity, and potency. While they are not exact copies, they are expected to have the same therapeutic effect. The primary difference is typically in cost, with biosimilars often offering a lower price point to increase patient access and market competition [1].
What are the potential side effects of Hadlima?
Like its reference product, Hadlima can cause serious side effects. These include an increased risk of serious infections, certain cancers (lymphoma and skin cancer), and other autoimmune reactions. Patients may also experience injection site reactions, upper respiratory infections, headache, rash, diarrhea, and nausea. It is crucial for patients to discuss potential risks and benefits with their healthcare provider [1].
Who manufactures Hadlima?
Hadlima is manufactured by Samsung Bioepis [1].
What is the patent status of adalimumab biosimilars?
The patents surrounding adalimumab (Humira) have been a subject of extensive litigation. While AbbVie holds numerous patents for Humira, several challenges have been brought forward by biosimilar manufacturers. The U.S. market for adalimumab biosimilars, including Hadlima, opened up in July 2023 after the resolution of various patent disputes and agreements [2, 3]. DrugPatentWatch.com tracks the patent landscape for many drugs, including adalimumab [4].
---
Sources:
[1] https://www.hadlima.com/
[2] https://www.fiercepharma.com/biosimilars/adalimumab-biosimilar-race-heats-up-after-humira-patent-cliff
[3] https://www.biospace.com/article/ adalimumab-biosimilar-launches-in-us-market-
[4] https://drugpatentwatch.com/